Back
HCV Populations 
Children & Adolescents
Children & Adolescents
FDA Approves Pegasys plus Ribavirin for Children with Chronic Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 August 2011 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) has approved pegyalted interferon alfa-2a (brand name Pegasys) plus ribavirin (brand name Copegus) for previously untreated children and adolescents age 5-17 with chronic hepatitis C virus (HCV) infection. 
HCV Polymerase Inhibitor PSI-938 Gets Fast Track Status
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 August 2011 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) last week granted a "fast track" designation for PSI-938, an investigational nucleotide analog hepatitis C virus (HCV) polymerase inhibitor being developed by Pharmasset.
Web Design and Development by